Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 222 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ondansetron Clear all
Completed Phase 1 Interventional Results available

A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)

NCT00819039
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Aprepitant, Ondansetron
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Months to 17 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 17, 2026, 3:38 AM EDT
Completed No phase listed Observational Results available

Ondansetron and the QT Interval In Adult Emergency Department Patients

NCT01759420
View directory record Official record
Conditions
Ondansetron
Interventions
Ondansetron
Drug
Lead sponsor
C.R.Darnall Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Fort Hood, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 17, 2026, 3:38 AM EDT
Completed Phase 4 Interventional

Examining the Effect of Ondansetron on Bowel Prep Success

NCT05439772
View directory record Official record
Conditions
Abdominal Pain, Inflammatory Bowel Diseases, Eosinophilic Gastroenteritis, Diarrhea, Hematochezia, Weight Loss
Interventions
Ondansetron
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
2 Years to 20 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 17, 2026, 3:38 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

NCT02592707
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Satoreotide tetraxetan, Amino acid solution, Antiemetic
Drug · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 17, 2026, 3:38 AM EDT
Completed Phase 2 Interventional Results available

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

NCT00954941
View directory record Official record
Conditions
Hematologic Diseases, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia
Interventions
Ondansetron, Aprepitant
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Oct 17, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers

NCT01572012
View directory record Official record
Conditions
Healthy
Interventions
Ondansetron, Ondansetron + Hylenex, Zofran ODT, Ondansetron solution
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
19 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 17, 2026, 3:38 AM EDT
Withdrawn Phase 2 Interventional

Chemo-embolization for Head and Neck Cancer

NCT04595981
View directory record Official record
Conditions
SCCHN, Squamous Cell Carcinoma
Interventions
Cisplatin
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 17, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults

NCT00437229
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant (GW679769) Oral Tablets, dexamethasone, ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 17, 2026, 3:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effectiveness of Naltrexone and/or Ondansetron to Reduce Craving for Alcohol and Drinking

NCT00183222
View directory record Official record
Conditions
Alcohol Dependence
Interventions
naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2010 · Synced Oct 17, 2026, 3:38 AM EDT
Completed Phase 2 Interventional Results available

New Medication Treatment for Stimulant Dependence

NCT00689572
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 17, 2026, 3:38 AM EDT
Completed Phase 3 Interventional Results available

Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation

NCT01536392
View directory record Official record
Conditions
Cancer of the Cervix
Interventions
Granisetron, Ondansetron, Questionnaires, Study Drug Diary
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 17, 2026, 3:38 AM EDT
Terminated Phase 1 Interventional Results available

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

NCT05035407
View directory record Official record
Conditions
Kita-kyushu Lung Cancer Antigen 1, Human
Interventions
IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR, Fludarabine, EKG, CXR, CT, MRI, PET, Biopsy, Acetaminophen, Ondansetron, Meperidine, Indomethacin, Famotidine
Drug · Biological · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 17, 2026, 3:38 AM EDT
Completed Not applicable Interventional Results available

Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)

NCT02473042
View directory record Official record
Conditions
Post-Operative Nausea and Vomiting, Breast Cancer
Interventions
Electrical Stimulation, Zofran, Dexamethasone, Phenergan, Pepcid, Questionnaire
Procedure · Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 17, 2026, 3:38 AM EDT
Completed Phase 1 Interventional

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

NCT02648490
View directory record Official record
Conditions
Solid Tumour
Interventions
HLX07, Acetaminophen, dexamethasone, diphenhydramine, 5-HT3 inhibitor
Drug
Lead sponsor
Henlix, Inc
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 17, 2026, 3:38 AM EDT
Terminated Phase 3 Interventional Results available

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

NCT04503668
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA), Olanzapine, Compazine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 17, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Results available

Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

NCT03030417
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
LMP744, Ondansetron, Olanzapine, Lorazepam, Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate, Loperamide, Diphenhydramine, Steroid, Epinephrine
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 17, 2026, 3:38 AM EDT
Completed Not applicable Interventional

Anesthetics in Rhytidoplasty - A Comparison Study

NCT02410460
View directory record Official record
Conditions
Rhytidoplasty
Interventions
clonidine, glycopyrrolate, propofol, ketamine, marcaine, scopolamine, midazolam, ondansetron, metoclopramide, lidocaine, famotidine, desflurane, sevoflurane
Drug · Device
Lead sponsor
Mercy Facial Plastic Surgery Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 17, 2026, 3:38 AM EDT
Completed Not applicable Interventional Results available

Continuous Subpleural Infusion of Bupivacaine

NCT01566838
View directory record Official record
Conditions
Postoperative Pain
Interventions
Subpleural pain catheter with infusion of 0.125% bupivacaine, Standard acute pain management
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Oct 17, 2026, 3:38 AM EDT
Withdrawn Phase 2 Interventional

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

NCT00723658
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bortezomib, carmustine, cisplatin, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, melphalan, thalidomide, autologous-autologous tandem hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
29
States / cities
Hartford, Connecticut • Beech Grove, Indiana • Richmond, Indiana + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 17, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mg

NCT00648804
View directory record Official record
Conditions
Healthy
Interventions
Ondansetron Orally Disintegrating Tablets 8 mg, Zofran ODT® Tablets 8 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 17, 2026, 3:38 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery?

NCT05021263
View directory record Official record
Conditions
Colo-rectal Cancer, Anesthesia
Interventions
IV Medications, placebo
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 17, 2026, 3:38 AM EDT
Withdrawn Not applicable Interventional

Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting

NCT00699894
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
aprepitant 40 mg, ondansetron 4 mg
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 25 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Oct 17, 2026, 3:38 AM EDT
Terminated Phase 3 Interventional Results available

Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis

NCT05065567
View directory record Official record
Conditions
Cyclic Vomiting Syndrome
Interventions
Droperidol, Haloperidol, Ondansetron 8mg
Drug
Lead sponsor
Corewell Health South
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Saint Joseph, Michigan
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 17, 2026, 3:38 AM EDT
Completed Phase 1 Interventional

AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies

NCT03313557
View directory record Official record
Conditions
Solid Tumors
Interventions
Wee-1 kinase inhibitor AZD1775
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 17, 2026, 3:38 AM EDT